Komagane

Researchers are studying the serum leucine-rich 2-glycoprotein LRG level to see if it can predict histologic remission in patients with ulcerative colitis UC. The study aims to clarify the specific LRG level that indicates histologic remission, which may serve as a noninvasive biomarker for monitoring disease activity in UC. This observational research is conducted by Showa Inan General Hospital. Participants with UC will have their serum LRG levels measured using an enzyme-linked immunosorbent assay. Colonoscopy with histologic examination is performed when histologic remission is predicted, regardless of symptoms or serum LRG values. Clinical remission is determined by a partial Mayo score of 0 or 1, endoscopic remission by a Mayo endoscopic subscore of 0, and histologic remission by a Geboes score less than 2. During the study, participants will undergo colonoscopies with histology to confirm remission status. The diagnostic ability of LRG to predict histologic remission will be analyzed using receiver operating characteristic ROC curves. The primary outcome is histologic remission of UC assessed within one week, and endoscopic remission is also evaluated. The study runs until December 2027 and includes patients aged 20 to 90 years.

Researchers are studying the bleeding rates after upper and lower gastrointestinal endoscopy procedures, including biopsies and polypectomies, in patients who continue to take antithrombotic medications. The study focuses on bleeding events that require endoscopic treatments such as hemostatic clipping. Immediate bleeding is defined as spurting or oozing lasting more than 30 seconds, while delayed bleeding occurs within two weeks after the procedure. The procedures studied include biopsy, cold or hot snare polypectomy, and endoscopic mucosal resection EMR. Patients do not receive preventive clipping after biopsies or polypectomies. The study also examines the rate of injured submucosal arteries in tissue samples when bleeding occurs. Participants will be monitored for up to 10 years to track rates of delayed and immediate bleeding and the number of clips used during treatment. This observational study involves regular assessments of bleeding complications related to endoscopic procedures while patients continue their antithrombotic therapy.

This trial is focused on patients with suspected or known common bile duct stones measuring 10 mm or larger. Researchers are comparing the effectiveness of two types of basket catheters, the Vortic Catch V basket catheter and an ordinary basket catheter, in removing these stones. The study is randomized and aims to evaluate how well each device clears stones during procedures following endoscopic papillary large balloon dilation. Participants will undergo stone removal procedures using either the Vortic Catch V basket catheter or the ordinary basket catheter after balloon dilation of the bile duct opening. This comparison aims to assess the removal ability of the two devices when used in this specific clinical setting. The study involves a parallel design where participants are randomly assigned to one of the two catheter groups. During the trial, participants will be monitored for the percentage of stones cleared and the total procedural time. Researchers will also track adverse events and any morbidities or mortality occurring within 30 days after the procedure. The study is designed to provide detailed information on the performance and safety of these devices for bile duct stone removal, with the trial expected to conclude by the end of 2026.

This research aims to evaluate the effectiveness and safety of Etrasimod, a novel oral drug, in elderly patients aged 65 years or older who have active ulcerative colitis. The study is focused on treatment and involves elderly patients with this condition to better understand the drugs impact on their disease course and symptoms. Participants will receive 2 mg of Etrasimod daily by mouth. The study is a single-group interventional trial where all participants receive the same treatment. The main treatment period includes assessment of clinical remission after 4 weeks, with additional evaluation of endoscopic improvements and monitoring for adverse events continuing up to 52 weeks. During the study, researchers will collect and analyze clinical data, adverse events, endoscopic findings, and tissue biopsy results from participants. The primary outcome is the rate of clinical remission at 4 weeks measured by a clinical activity index. Secondary outcomes include endoscopic improvements and safety monitoring over one year. Participants will be monitored throughout the study to assess both efficacy and safety of the medication.

This trial evaluates the traditional Japanese medicine Keishi-ka-shakuyaku-daio-to TJ-134 in patients with symptomatic pneumatosis cystoides intestinalis PCI. It compares the effects of TJ-134 with a control treatment, lactomin, over an 8-week period. The study aims to understand how these treatments affect abdominal symptoms and CT findings related to PCI. Participants are randomly assigned to receive either TJ-134 7.5g per day, which contains a mixture of peony root, cinnamon bark, jujube, glycyrrhiza, rhubarb, and ginger, or lactomin 3g per day for 8 weeks. Treatment is administered daily, and the study uses a parallel-group design with randomization to one of the two treatments. Throughout the study, abdominal symptoms are assessed and abdominal CT scans are performed at enrollment and after 8 weeks of treatment. Researchers measure changes in CT findings and symptom improvements such as bloating and abdominal pain. This helps evaluate the treatment effects on PCI over the treatment period under the supervision of the research team.